H.C. Wainwright lowered the firm’s price target on Coherus Biosciences to $13 from $20 and keeps a Buy rating on the shares. The anlayst is taking a more conservative view on toripalimab’s launch into new indications.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CHRS:
- Coherus Biosciences reports Q3 EPS (27c), consensus (31c)
- Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
- CHRS Earnings this Week: How Will it Perform?
- Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)
- Coherus Biosciences presents data from next-generation immuno-oncology programs
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue